Cash, cash equivalents and investments totaled $228.2M as of December 31 , which the company expects will be sufficient to fund its operating plan into the first half of 2025.."We had a productive 2022, during which we made significant progress across our clinical pipeline, advanced multiple preclinical discovery programs, and further strengthened the balance sheet," said Jacob M. Chacko, MD, chief executive officer. "We commenced dosing for all three Phase 1b trials in 2022 and selected a drug candidate for our potential first-in-class PLK4 inhibitor. We are pleased with the ongoing enrollment across our three Phase 1b trials and are looking forward to sharing initial clinical data for ORIC-533, ORIC-114, and ORIC-944 in the second half of 2023."
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on ORIC:
- ORIC Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Operational Updates
- Oric Pharmaceuticals upgraded to Outperform from Perform at Oppenheimer
- ORIC Pharmaceuticals Announces Multiple Presentations at the 2023 American Association for Cancer Research (AACR) Annual Meeting
- ORIC Pharmaceuticals to Participate in the Oppenheimer 33rd Annual Healthcare Conference
- ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)